Lassa fever presents a formidable diagnostic challenge. Early symptoms, including fever, malaise, headache, and muscle pain, overlap substantially with malaria, typhoid fever, and other common febrile illnesses that dominate the clinical landscape of the region. As a result, many infections are treated empirically as malaria and never confirmed as Lassa, obscuring the true burden of disease and delaying interventions such as isolation, contact tracing, and timely administration of ribavirin, the antiviral most often used in management. Case fatality is highest among patients hospitalized late in illness, which makes early laboratory confirmation not merely an academic exercise but a direct determinant of survival.

Historically, suspected cases in Forest Guinea had to be referred to distant reference laboratories, often outside the country, for confirmatory testing. Transport of samples over long distances on poor roads introduced delays of days or weeks, degraded sample quality, and severed the connection between laboratory results and the clinical decisions that needed to inform them. During that interval, patients could deteriorate, contacts could be exposed, and outbreak signals could be missed entirely. Strengthening in-country and, ultimately, in-region diagnostic capacity has therefore been a central pillar of Guinea’s post-epidemic health security agenda, accelerated by the hard lessons of the 2014–2016 Ebola virus disease epidemic in West Africa.

The advances described in the study center on the establishment and progressive improvement of laboratory platforms capable of detecting Lassa virus and other hemorrhagic fever pathogens at or near the point of patient care. Molecular assays based on reverse transcription polymerase chain reaction (RT-PCR) remain the reference standard for acute case confirmation, targeting conserved regions of the viral S segment genome. Deploying these assays in Guinea required not only equipment and reagents but also reliable cold chains, uninterrupted power supply, quality management systems, and, critically, trained personnel able to perform testing to internationally recognized standards.

Serological methods complement molecular detection in the diagnostic arsenal. Indirect immunofluorescent antibody tests and enzyme-linked immunosorbent assays detecting Lassa-specific IgM and IgG antibodies extend the window of detection beyond the viremic phase and support seroprevalence studies that map the footprint of past transmission. Because antibody responses in Lassa fever can be variable and cross-reactivity with other arenaviruses complicates interpretation, the combination of molecular and serological approaches, applied with careful clinical context, provides the most complete picture of who is infected, who has been exposed, and where the virus is actively circulating.

A decisive element of the capacity-building effort has been the training of Guinean laboratory scientists and technicians in biosafe specimen handling, nucleic acid extraction, assay execution, and result interpretation. Working with Lassa virus requires appropriate biosafety precautions, since the virus can be transmitted through contact with infectious blood, tissues, or bodily fluids, and laboratory-acquired infections are a recognized occupational risk. Building a cadre of locally based experts reduces dependence on external missions, sustains testing throughput between outbreaks, and anchors diagnostic capability within the national public health system rather than in temporary emergency structures.

The study documents how these investments translated into operational gains: more suspected cases tested, shorter turnaround times between sample collection and result reporting, and a higher proportion of Lassa fever cases confirmed within the country. Each of these metrics matters. Faster confirmation enables clinicians to initiate appropriate treatment earlier, triggers more rapid deployment of outbreak response teams, and improves the accuracy of surveillance data used to allocate scarce resources. Improved detection also feeds back into research, since confirmed cases provide the samples and epidemiological context needed to study viral diversity, disease severity, and transmission dynamics.

Genomic surveillance is an increasingly important downstream benefit of strengthened diagnostics. Sequencing Lassa virus genomes from confirmed cases allows researchers to track viral lineages, identify introductions from rodent reservoirs into human populations, and reconstruct transmission chains. In Forest Guinea, where multiple Lassa virus lineages are known to circulate and where the ecological interface between humans and reservoir rodents is intimate, genomic data can distinguish persistent local transmission from repeated spillover events, information that shapes whether interventions should prioritize rodent control, food storage hygiene, community education, or vaccination once candidate vaccines advance through the pipeline.

The Guinea experience also carries lessons for regional health security more broadly. The same laboratory infrastructure, trained workforce, and specimen referral networks that support Lassa fever detection can be adapted for other viral hemorrhagic fevers, including Ebola, Dengue, and yellow fever, as well as for emerging pathogens of unknown origin. Integrated diagnostic platforms that can pivot between pathogens represent a more resilient investment than single-disease silos, a principle reinforced by the COVID-19 pandemic, which tested and in many places benefited from hemorrhagic fever diagnostic networks established in the preceding decade.

Challenges remain. Sustaining funding beyond donor-supported emergency cycles, maintaining reagent supply chains, retaining skilled staff, and expanding testing to peripheral health facilities all require continued commitment. Yet the trajectory documented in Forest Guinea demonstrates that endemic countries can move from being sample-shippers to being diagnostic leaders in the fight against viral hemorrhagic fevers. Every Lassa fever case confirmed quickly and accurately is a patient treated sooner, a contact list initiated earlier, and a piece of evidence added to the regional understanding of one of West Africa’s most persistent viral threats.

Subject of Research: Strengthening diagnostic capacity for Lassa fever and viral hemorrhagic fevers in Forest Guinea

Article Title: Strengthening diagnostic capacity for viral hemorrhagic fevers in Forest Guinea: advances in Lassa fever case detection

Article References: Koundouno, F. R., Sidibe, Y., Millimono, S. L., Ifono, K., Hinzmann, J., Soubrier, H., Kourouma, K., Millimouno, T. E., Tolno, F. M., Kamano, F. M., Barry, M. D., Koulemou, S., Sonomy, B., Traore, M., Keïta, K., Hinrichs, M., Ryter, S., van Gelder, C., Becker-Ziaja, B., … Annibaldis, G. (2026). Strengthening diagnostic capacity for viral hemorrhagic fevers in Forest Guinea: advances in Lassa fever case detection. npj Viruses, 4(1), Article 42. https://doi.org/10.1038/s44298-026-00239-9

Image Credits: AI Generated

DOI: 10.1038/s44298-026-00239-9

Keywords: Lassa fever, viral hemorrhagic fevers, diagnostic capacity, Forest Guinea, RT-PCR, serology, genomic surveillance, biosafety, public health laboratory, case detection, outbreak response, Strengthening

Quantitative reverse transcription polymerase chain reaction testing returned cycle threshold values of 35 and 36, numbers that indicate a very low systemic viral burden. In the arithmetic of viral haemorrhagic fevers, high viraemia generally tracks with severe disease and poor outcomes, while low viral loads are usually reassuring. Yet this patient, with barely detectable virus circulating in her blood, was experiencing some of the most severe neuropsychiatric distress her care team had encountered in Lassa fever. The dissociation between her laboratory values and her clinical state is the central puzzle of the report, authored by Amos Egbedion Unuane of the Federal Medical Centre in Owo and Ambrose Alli University in Ekpoma, together with colleagues from microbiology, community medicine, chemical pathology and psychiatry departments in Nigeria.

The epidemiological backdrop matters. Nigeria remains the global epicentre of Lassa fever, an arenavirus infection transmitted to humans primarily through contact with food or household items contaminated by the urine and faeces of Mastomys rodents, particularly the multimammate mouse Mastomys natalensis. The disease has traditionally been classified as a viral haemorrhagic illness, characterised by systemic symptoms and the potential for catastrophic bleeding. But the authors note that evolving clinical patterns suggest neuropsychiatric manifestations are becoming increasingly prominent, particularly in Ondo, Edo and Bauchi States. Crucially, these neurological and psychiatric features often appear in patients who lack classic haemorrhagic signs, creating a real risk that they will be misdiagnosed as primary psychiatric disorders or as complicated malaria.

That diagnostic trap played out in this very case. The patient’s initial presentation was misread as complicated malaria, a mistake the authors describe as emblematic of the challenges facing clinicians in endemic hotspots, where atypical presentations of Lassa fever are increasingly documented. Malaria is far more common and its symptoms overlap broadly with early Lassa fever, so the default assumption in a febrile patient is understandable. But the presence of a focal seizure, followed by escalating psychiatric symptoms, should have served as a red flag. The report argues that acute psychiatric changes, refractory insomnia and seizures should be treated as critical clinical clues that warrant prompt evaluation for Lassa fever, even when haemorrhage is absent and viral loads are low.

The timeline of the infection adds another instructive detail. Seven days before her hospital admission, the patient had identified and disposed of a Mastomys species rodent at her residence. This history of rodent contact, obtained through careful clinical interviewing, provided the epidemiological link that ultimately pointed the diagnostic workup toward Lassa fever. In endemic regions, the authors suggest, such environmental histories should be actively sought in any patient presenting with fever and unexplained neurological or psychiatric features, because the window for effective treatment narrows rapidly as the infection progresses.

Treatment followed established protocols. The patient received a full course of intravenous ribavirin, the only widely available specific antiviral therapy for Lassa fever, alongside targeted supportive and symptomatic management. The response was gratifying: she achieved complete clinical recovery, with resolution of all neurological and psychiatric deficits. The outcome demonstrates that even severe neuropsychiatric complications of Lassa fever can be reversible when the diagnosis is made and appropriate therapy is delivered, reinforcing the argument that early recognition of atypical presentations is not merely an academic exercise but a determinant of survival and long-term neurological health.

The mechanistic implications of the case are perhaps its most scientifically provocative element. The authors propose two non-exclusive explanations for the marked clinico-biological dissociation they observed. The first is direct viral neurotropism: the possibility that Lassa virus, an Old World arenavirus, can invade and replicate within cells of the central nervous system, causing injury that is invisible to measurements of viral RNA in peripheral blood. The second is a sequestered neuro-inflammatory response, in which immune activity within the brain and spinal cord proceeds independently of the systemic viral burden measured in the bloodstream. Either scenario would explain how a patient with cycle threshold values of 35 and 36, indicating minimal circulating virus, could manifest seizures, tremors, emotional instability and insomnia so severe that sedation failed.

Central nervous system involvement in Lassa fever is not entirely without precedent, but the timing described in this report is notable. The authors emphasise that central nervous system morbidity may present early in the clinical course of the disease, even in the absence of an overt systemic crisis. This challenges the conventional staging of the illness, in which neurological complications are typically regarded as late phenomena of severe, high-viraemia disease. If early neuropsychiatric involvement is more common than previously appreciated, the true burden of Lassa fever-related neurological injury in endemic regions may be substantially underestimated, both because such cases go undiagnosed and because survivors with psychiatric sequelae may never be linked back to their antecedent infection.

The practical consequences of this case report extend into public health policy. The authors call for the integration of neuro-phenotyping, the systematic characterisation of neurological and psychiatric features, into revised clinical management strategies for Lassa fever. They also stress the urgency of stringent environmental rodent control, since prevention of infection at its source remains the most reliable safeguard in communities where Mastomys rodents live in close proximity to human dwellings and food stores. For frontline hospitals in Ondo, Edo, Bauchi and beyond, the message is that a febrile patient with new seizures, agitation or intractable insomnia deserves consideration of Lassa fever regardless of whether bleeding is present or viral load assays suggest a mild infection.

The report, published open access on 12 September 2026 after acceptance by BMC Infectious Diseases, was conducted in accordance with the Declaration of Helsinki, with an ethical exemption from the Health Research Ethics Committee of the Federal Medical Centre, Owo, and written informed consent from the patient for publication. It received no specific external funding. Its authors, drawn from the Federal Medical Centre’s departments of medical microbiology, community medicine, chemical pathology and psychiatry, along with Ambrose Alli University and Achievers University, argue that their single case carries a broad warning: neuropsychiatric symptoms may be significant in Lassa fever even without haemorrhage or high viral loads. In a disease that infects thousands of Nigerians each year and remains dramatically under-reported, recognising the brain as an early and independent target of the virus could reshape triage, testing and treatment across the endemic belt.

Subject of Research: Neuropsychiatric complications of clinically mild, low-viraemia Lassa fever in Nigeria

Article Title: Neuropsychiatric complications of clinically mild lassa fever with low viraemia: a case report from a global hotspot in Owo, Ondo State, Nigeria

Article References: Unuane, A. E., Oko-Uromi, D. O., Adedosu, N. A., Ayodeji, O. O., Raji, S. O., Osagbaekhoe, A. A., & Azegbeobor, J. O. (2026). Neuropsychiatric complications of clinically mild lassa fever with low viraemia: a case report from a global hotspot in Owo, Ondo State, Nigeria. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14434-9

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14434-9

Keywords: Lassa fever, neuropsychiatric, Mastomys natalensis, low viraemia, seizure, insomnia, ribavirin, Nigeria, Owo, viral neurotropism, malaria misdiagnosis, rodent control